Create Account | Sign In: Author or Forum

Search Symptoms

Category: Cardiology | Family Medicine | Internal Medicine | Journal

Back to Journal Articles

Non-HDL Cholesterol Levels Linked to Long-Term ASCVD Risk

Last Updated: December 04, 2019.

Elevated concentrations of non-high-density lipoprotein cholesterol are associated with an increased long-term risk for atherosclerotic cardiovascular disease, according to a study published online Dec. 3 in The Lancet.

WEDNESDAY, Dec. 4, 2019 (HealthDay News) -- Elevated concentrations of non-high-density lipoprotein (non-HDL) cholesterol are associated with an increased long-term risk for atherosclerotic cardiovascular disease, according to a study published online Dec. 3 in The Lancet.

Fabian J. Brunner, M.D., from the University Heart & Vascular Center Hamburg in Germany, and colleagues examined the cardiovascular disease risk associated with the spectrum of bloodstream non-HDL cholesterol concentrations. In addition, a tool was created to estimate the probabilities of a cardiovascular disease event by age 75 years.

A total of 398,846 individuals belonging to 38 cohorts were identified; the derivation and validation cohorts included 199,415 and 199,431 individuals, respectively. The researchers identified 54,542 cardiovascular end points during a maximum follow-up of 43.6 years. For increasing non-HDL cholesterol categories, incidence curve analyses showed progressively higher 30-year cardiovascular disease event rates. For both sexes, in multivariable analysis with non-HDL cholesterol lower than 2.6 mmol/L as reference, there was an increase noted in the association between non-HDL cholesterol concentration and cardiovascular disease. Cardiovascular disease event probabilities specific for non-HDL cholesterol could be estimated with the derived tool, with high comparability seen between the derivation and validation cohorts. A 50 percent decrease in non-HDL cholesterol concentration correlated with reduced cardiovascular disease event risk by age 75 years; the risk reduction was greater with earlier reductions in cholesterol concentrations.

"Our study provides unique insights into the benefits of a potential early intervention in primary prevention," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)


Previous: Adults Not Living in Metro Areas Have Reduced Access to Care Next: Services Affected by Rural Hospitals Joining Health Systems

Reader comments on this article are listed below. Review our comments policy.


Submit your opinion: